Bayer

This study tests a new daily pill, sevabertinib, against standard intravenous chemotherapy for people with advanced non-small cell lung cancer that has specific HER2 mutations. About 444 adults will take either the pill or standard treatment. The goal is to see if the pill delays…

This study tests a new drug, BAY 3401016, in 60 adults aged 18 to 45 with Alport syndrome, a rare genetic condition that damages kidneys. The drug blocks a protein thought to cause kidney harm, aiming to slow the loss of kidney function. Participants receive either the drug or a …

This study tests a drug called finerenone in children aged 6 months to 18 years who have heart failure and a weakened heart pump. The drug aims to reduce heart stress and improve function. About 111 children will receive either finerenone or a placebo for 3 months, alongside thei…

This program offers an experimental oral medication, sevabertinib, to adults with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has stopped responding to other treatments. Participants must have a life expectancy of at least 12 weeks and be in rel…

This study tests a new drug, BAY 3547926, for people with advanced liver cancer that has a specific protein called GPC3. The drug delivers a small amount of radiation directly to cancer cells to kill them while sparing healthy tissue. About 148 participants will receive different…

This study tests a drug called acoramidis in 50 adults with a heart condition called ATTR-CM, where a protein builds up and weakens the heart. Participants have already been taking a similar drug (tafamidis) and will switch to acoramidis for 6 months. The main goal is to see if a…

This study follows 480 people with neovascular glaucoma, a serious eye condition that can cause vision loss. Researchers are tracking how well the drug Eylea works and what side effects occur when used in routine medical care. Participants receive Eylea injections and are monitor…

This study tests a drug called darolutamide, added to standard hormone therapy, for Indian men with a type of prostate cancer that hasn't spread but is growing despite low testosterone. The main goal is to check safety and side effects in this group. About 50 men will take darolu…

This study tests a new medicine, BAY 3389934, in people with sepsis who develop a dangerous blood clotting problem. The goal is to find a safe dose and see how the drug affects the body. About 36 adults in the ICU will take part, and the study lasts around 28 days.

This study tests an oral drug called BAY 2927088 in people with advanced solid tumors that have HER2 mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. About 111 adults with various cancers (excluding lung cancer) will take the drug daily until th…

This study is for men with high-risk localized prostate cancer who plan to have their prostate removed. Before surgery, participants will receive darolutamide (a pill that blocks male hormones) plus standard hormone therapy for either 12 or 24 weeks. The goal is to see which trea…

This early-phase study tests whether adding an experimental SOS1 inhibitor (BAY 3498264) to the approved drug sotorasib can improve outcomes for people with advanced solid tumors that have a specific KRAS G12C mutation. About 104 participants whose cancer has worsened after stand…

This study is checking the safety of a drug called darolutamide in Korean men with a type of prostate cancer that hasn't spread or has spread but responds to hormone therapy. The drug works by blocking male hormones that help cancer grow. Researchers will track side effects and s…

This study tests a new drug, BAY 3713372, in people with solid tumors that lack a gene called MTAP. The drug blocks a protein that these cancer cells need to survive, potentially killing them while leaving healthy cells alone. The trial first finds the safest dose, then tests how…

This early-stage study tests a new drug, 225Ac-PSMA-Trillium, in people with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug delivers radiation directly to cancer cells to damage and stop their growth. The main goals are to check safet…

This study follows 100 adults and children with advanced or recurrent TRK fusion cancer who are taking larotrectinib as part of their routine care. Researchers will collect information from medical records and interviews to learn about side effects and how well the drug controls …

This study tests whether adding finerenone to standard blood pressure medicines can reduce protein in the urine of children aged 6 months to 18 years with chronic kidney disease. About 219 participants will receive either finerenone or a placebo for 6 months. The goal is to see i…

This study tests a new drug, BAY 3771249, for people with advanced colorectal cancer that has a specific change in the KRAS gene (G12D). The drug aims to block the faulty protein and slow or stop cancer growth. About 130 adults will receive the drug alone or with another drug cal…

This study looks at the long-term safety of adding finerenone to standard blood pressure medicines for children aged 1 to 18 with chronic kidney disease and proteinuria (protein in urine). About 100 kids who were in an earlier study will take finerenone for up to 18 months. Resea…

This study tests a nasal gel for people with a stuffy nose from colds or allergies. The gel contains a common decongestant in a new form that may stay in the nose longer. Researchers want to see how well it works and if it is safe for adults aged 18 to 65.

This study observes 300 people with Parkinson's disease who still have movement problems despite taking standard medications. Researchers will collect data over up to 5 years to understand how the disease changes, how treatments work in real life, and the challenges patients and …

This study tracks 1,350 Korean adults with chronic heart failure who are prescribed Verquvo as part of their usual care. Researchers will monitor side effects and heart-related events over up to 12 months to see how safe and effective the drug is in everyday practice. No experime…

This study reviews medical records of 1,400 men with metastatic hormone-sensitive prostate cancer (mHSPC) to see how darolutamide is used in everyday urology clinics. It compares two treatment approaches: darolutamide plus hormone therapy alone (doublet) or with chemotherapy (tri…

This study looks at how often preterm babies with retinopathy of prematurity (ROP) receive the medicine Eylea using a special pediatric dosing device in the UK. Researchers will collect data from a national database on up to 200 babies born between 2024 and 2026. The goal is to s…

This study watches how well the drug VITRAKVI (larotrectinib) works and how safe it is for people with TRK fusion cancers that have spread. About 150 adults and children will be followed for 2 to 5 years as part of their normal care. The goal is to learn more about the drug's rea…

This study looks at how women treated their menopause hot flashes before and after taking part in the OASIS clinical trials. Researchers will survey past participants and review their medical records to see which treatments they used, whether they stuck with them, and why they st…

This study looks at why some people develop sudden kidney injury after heart surgery. Researchers will collect blood and urine samples from 200 adults scheduled for heart surgery to measure certain biological markers. The goal is to better understand how kidney injury develops, w…

This study looks at health records from 50,000 people in Germany to find out how common three eye diseases—nAMD, DME, and RVO—are and how they've changed from 2009 to 2024. Researchers will compare two large data sources to see trends and what factors like age or other health iss…

This study is observing 500 adults in South Korea with chronic kidney disease and type 2 diabetes who are taking the medication finerenone as part of their regular care. Researchers want to learn why doctors prescribe it, how long patients stay on it, and what side effects occur.…

This early-stage study tests a new drug, BAY 3389934, in up to 16 healthy Japanese adults aged 18-55. The main goal is to check the drug's safety and how the body handles it at different doses. Participants receive either the drug or a placebo by IV infusion and are closely monit…

This study looks at prescription records from 1,000 men in Australia with advanced prostate cancer that still responds to hormone therapy. Researchers want to see which drug combinations doctors are actually prescribing and how well patients stick with their treatment. No new tre…

This study watches how a new medication, acoramidis, works in daily life for people with a serious heart condition called ATTR-CM. Researchers will track up to 2,000 adults in Europe to see how the drug is used, how safe it is, and how it affects heart function and quality of lif…

This observational study looks at Japanese men with low-volume metastatic hormone-sensitive prostate cancer (mHSPC) who are taking darolutamide along with standard hormone therapy and chemotherapy. The goal is to see how safe the combination is and how well it works in everyday m…

This study looks at the safety of finerenone, a drug already approved for chronic heart failure, in 300 adults in South Korea. Participants take the drug as prescribed by their doctor, and researchers collect data from routine care for one year. The goal is to see how safe and ef…

This study follows about 20 Korean people aged 12 and older with hemophilia A who are already taking Jivi as prescribed by their doctor. Researchers will collect information from routine clinic visits to see how safe the drug is in real-world use. No extra tests or visits are req…

This study follows 1400 Japanese people with chronic heart failure who are prescribed vericiguat by their doctors. Researchers will track side effects and heart-related deaths over two years to see how safe the drug is in real-world use. Participants continue their normal treatme…

This study looks at real-world data from 50,000 people in Asia and the US who have both chronic kidney disease and type 2 diabetes and are taking the drug finerenone as part of their regular care. Researchers will collect information on patients' age, other health conditions, and…